134
Participants
Start Date
April 8, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
September 30, 2026
LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine
"LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody.~Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine."
Tislelizumab+Oxaliplatin+Capecitabine
"Tislelizumab is a humanized monoclonal antibody against Programmed cell death -Ligand-1(PD-1).~Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine."
LM-108 injection 10mg/kg +penpulimab
"LM-108injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody."
LM-108 injection 600mg + penpulimab
"LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody."
RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
The First Hospital Of China Medical University, Shenyang
NOT_YET_RECRUITING
Jilin Cancer Hospital, Changchun
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
NOT_YET_RECRUITING
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
NOT_YET_RECRUITING
Jiangsu Provincial People's Hospital, Nanjing
NOT_YET_RECRUITING
NanJing Drum Tower Hospital, Nanjing
NOT_YET_RECRUITING
XuZhou Central Hospital, Xuzhou
NOT_YET_RECRUITING
Anhui Provincial Cancer Hospital, Hefei
NOT_YET_RECRUITING
Cancer Hospital of Shandong First Medical University, Jinan
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
NOT_YET_RECRUITING
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
The second xiangya hospital of central south university, Changsha
NOT_YET_RECRUITING
Hubei Cancer Hospital, Wuhan
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Nanyang Second General Hospital, Nanyang
NOT_YET_RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
NOT_YET_RECRUITING
Sichuan Cancer Hospita, Chengdu
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Xi'an
NOT_YET_RECRUITING
The First Hospital of Lanzhou University, Lanzhou
NOT_YET_RECRUITING
Gansu Wuwei Tumour Hospital, Wuwei
NOT_YET_RECRUITING
Xinjiang Medical University Affiliated Cancer Hospital, Ürümqi
NOT_YET_RECRUITING
The Second Hospital of Anhui Medical University, Hefei
NOT_YET_RECRUITING
Tangshan People's Hospital, Tangshan
NOT_YET_RECRUITING
Inner Mongolia Hospital of Peking University Cancer Hospita, Hohhot
NOT_YET_RECRUITING
First Hospital of Shangxi Medical University, Taiyuan
NOT_YET_RECRUITING
Shanxi Cancer Hospital, Taiyuan
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY